• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Ameritek Ventures
Apyx Medical Corporation - Common Stock
Eos Energy Enterprises, Inc. - Warrant
Everbright Digital Holding Limited - Ordinary Shares
Gap
House of Doge Inc. - Common Stock
Marfrig Global Foods Sa
ProShares Ultra SpaceX
Schmitt Industries, Inc. - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anika Therapeutics Inc. - Common Stock (NQ:ANIK)

21.09 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 21.09
Bid (Size) 18.00 (300)
Ask (Size) 21.50 (400)
Prev. Close 21.09
Today's Range 21.09 - 21.09
52wk Range 9.010 - 22.88
Shares Outstanding 14,828,456
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
October 22, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika (ANIK) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
Revenue hit $32.6 million with record commercial channel sales and expanded margins. 
Via The Motley Fool
Topics Earnings

Performance

52-Week Range 7.8% below 52-week high
21.09
9.0152W Low 22.8852W High
1 Week
19.841W Low 21.091W High

Anika Therapeutics Inc. - Common Stock (ANIK) traded between $9.01 and $22.88 over the past 52 weeks and last traded at $21.09, 7.8% below its 52-week high. Over the past week it ranged between $19.84 and $21.09.

Past 12 Months
+5.6%
+1.0%
+43.8%
+36.8%
+125.6%
+120.1%
1W +$1.11
1M +$0.20
3M +$6.42
6M +$5.67
YTD +$11.74
1Y +$11.51

ANIK was +120.1% over the past year, +36.8% over six months, +125.6% year to date, +5.6% in the last week.

12 Months vs Market
ANIK
+120.1%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months ANIK returned +120.1% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg
Today 1 3-mo avg 107.8K
1W
124.8K
1M
107.0K
3M
107.8K
6M
96.9K
YTD
113.3K
1Y
121.1K

ANIK most recently traded 1 shares against a 3-month average daily volume of 107.8K.

More News

Read More
News headline image
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 04, 2026
From American News Group
Via GlobeNewswire
Anika Therapeutics (NASDAQ:ANIK) Soars on Q2 Earnings Beat, Revenue and EPS Top Estimates ↗
July 29, 2026
Via Chartmill
Topics Earnings
Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat ↗
April 29, 2026
Via Chartmill
ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally ↗
February 26, 2026
Via Chartmill
Topics Earnings
News headline image
Anika Therapeutics Q2 Earnings Call Highlights ↗
July 29, 2026
Via MarketBeat
Topics Earnings
News headline image
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
July 15, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
April 30, 2026
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Anika (ANIK) Q1 2026 Earnings Transcript ↗
April 29, 2026
Via The Motley Fool
News headline image
Anika (ANIK) Q2 2025 Earnings Call Transcript ↗
April 21, 2026
Via The Motley Fool
Topics Earnings
News headline image
Anika (ANIK) Q4 2025 Earnings Call Transcript ↗
April 21, 2026
Via The Motley Fool
Topics Earnings
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
April 15, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
April 13, 2026
Via MarketMinute
News headline image
Telix Strengthens Board with Additional Director Appointments
April 08, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
February 18, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
February 12, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
January 26, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
January 23, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
Anika Therapeutics Announces Leadership Transition
January 08, 2026
From Anika Therapeutics Inc.
Via GlobeNewswire
News headline image
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
December 30, 2025
From Kirby McInerney LLP
Via Business Wire
News headline image
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
December 05, 2025
From Kirby McInerney LLP
Via GlobeNewswire

Frequently Asked Questions

Is Anika Therapeutics Inc. - Common Stock publicly traded?
Yes, Anika Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Anika Therapeutics Inc. - Common Stock trade on?
Anika Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anika Therapeutics Inc. - Common Stock?
The ticker symbol for Anika Therapeutics Inc. - Common Stock is ANIK on the Nasdaq Stock Market
What is the current price of Anika Therapeutics Inc. - Common Stock?
The current price of Anika Therapeutics Inc. - Common Stock is 21.09
When was Anika Therapeutics Inc. - Common Stock last traded?
The last trade of Anika Therapeutics Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Anika Therapeutics Inc. - Common Stock?
The market capitalization of Anika Therapeutics Inc. - Common Stock is 312.73M
How many shares of Anika Therapeutics Inc. - Common Stock are outstanding?
Anika Therapeutics Inc. - Common Stock has 313M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap